A Study to Learn About How a New Pneumococcal Vaccine Works in Adults
← catalyst calendarNCT07086677 · readout in 427 d
Sponsored by Pfizer (industry) · PFE — their whole pipeline →.
Phase
Phase 1
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Double · Prevention
Enrollment
380actual
Sites
20
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-07-22 | actual | When the study began enrolling |
| Primary completion | 2027-10-21 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-10-21 | estimated | The whole study's end, after follow-up |
| First posted | 2025-07-25 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-22 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Streptococcus Pneumoniae
Interventions
- Biological: PG4 vaccine in Buffer 1 with low dose PA-001
- Biological: PG4 in Buffer 1 with low dose PA-002
- Biological: PG4 in Buffer 1 with high dose PA-001
- Biological: PG4 vaccine in Buffer 1 with high dose PA-002
- Biological: PG4 vaccine in Buffer 2
- Biological: 20-valent pneumococcal conjugate vaccine
- Biological: Saline injection
Primary outcomes
what the primary-completion date above is the date OFPercentage of participants reporting prespecified local reactions after each dose.
measured Within 7 days after each study intervention.
Percentage of participants reporting prespecified systemic reactions after each dose.
measured Within 7 days after each study intervention.
Percentage of participants reporting adverse events.
measured From signing of the ICD to 1 month after last study intervention.
Percentage of participants reporting serious adverse events.
measured From signing of the ICD to 6 months after the last study intervention.
Percentage of participants reporting serious adverse events.
measured From signing of the ICD to 12 months after the last study intervention.
Percentage of participants with abnormal hematology and chemistry laboratory values.
measured Within 2 weeks after each study intervention.
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed